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Many disorders are associated with altered serum protein concentrations, including malnutrition, cancer, and cardiovascular, kidney,
and inflammatory diseases. Although these protein concentrations are highly heritable, relatively little is known about their underlying
genetic determinants. Through transethnicmeta-analysis of European-ancestry and Japanese genome-wide association studies, we iden-
tified six loci at genome-wide significance (p < 5 3 108) for serum albumin (HPN-SCN1B, GCKR-FNDC4, SERPINF2-WDR81,
TNFRSF11A-ZCCHC2, FRMD5-WDR76, and RPS11-FCGRT, in up to 53,190 European-ancestry and 9,380 Japanese individuals) and three
loci for total protein (TNFRS13B, 6q21.3, and ELL2, in up to 25,539 European-ancestry and 10,168 Japanese individuals). We observed
little evidence of heterogeneity in allelic effects at these loci between groups of European and Japanese ancestry but obtained substantial
improvements in the resolution of fine mapping of potential causal variants by leveraging transethnic differences in the distribution of
linkage disequilibrium. We demonstrated a functional role for the most strongly associated serum albumin locus, HPN, for which Hpn
knockout mice manifest low plasma albumin concentrations. Other loci associated with serum albumin harbor genes related to ribo-
some function, protein translation, and proteasomal degradation, whereas those associated with serum total protein include genes
related to immune function. Our results highlight the advantages of transethnic meta-analysis for the discovery and fine mapping of
complex trait loci and have provided initial insights into the underlying genetic architecture of serum protein concentrations and their
association with human disease.Albumin, the major plasma protein, transports endoge-
nous and exogenous compounds such as nutrients,
hormones, metabolic catabolites, and drugs andmaintains
intravascular volume by generating oncotic pressure.
Diverse conditions, including cancer, liver and kidney
diseases, and acute and chronic inflammatory states,
manifest reduced plasma albumin concentrations. Low
plasma albumin is associated with increased risk of cardio-
vascular disease1 and mortality.2 Gamma globulins, the
second most abundant type of plasma protein, are
composed primarily of immunoglobulins (Ig), the effector
arm of humoral immunity. Dysregulation of Ig may result
from altered production in infectious and autoimmune
diseases and in immunodeficiency syndromes and from
increased loss in kidney disease.3 To date, little is known
about the genetic regulation of plasma proteins, and the
pathophysiologic mechanisms leading to low albumin
concentrations in many acute and chronic disease condi-
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The Americdiscovery of pathways in the metabolism, regulation,
and/or disease processes associated with changes in these
proteins and may provide insights into the immune
system, cancer, inflammatory diseases, and malnutrition.
Serum albumin heritability estimates range from 0.36 to
0.77 in family and twin studies.4–7 Recent genome-wide
association studies (GWASs) of populations of eastern
Asian ancestry have revealed genetic loci contributing to
variation in blood protein concentrations: GCKR (MIM
600842)-FNDC4 (MIM 611905) to serum albumin,8
TNFRSF13B (MIM 604907) to total protein,8 and RPS11
(MIM 180471)-FCGRT (MIM 601437) to both traits.8,9
These associations have not been previously examined in
other ancestry groups, and much of the heritability of
blood protein concentrations remains unexplained. To
bridge this gap in our understanding of the genetic archi-
tecture of serum protein concentrations, we began by per-
forming a meta-analysis of European-ancestry GWASs for
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Table 1. Loci Achieving Genome-wide Significance for Serum Albumin and Total Protein in European-Ancestry Populations
Lead SNP Chr Position (Build 36)
Alleles
EAF Beta SE p Value Sample Size LocusEffect Other
Serum Albumin
rs4806073 19 40,247,030 C T 0.93 0.0257 0.0033 3.3 3 1015 53,187 HPN-SCN1B
rs1260326 2 27,584,444 T C 0.41 0.0124 0.0016 2.9 3 1014 53,189 GCKR-FNDC4
rs11078597 17 1,565,113 C T 0.18 0.0205 0.0029 6.8 3 1013 38,231 SERPINF2-WDR81
rs13381710 18 58,304,309 G A 0.30 0.0108 0.0018 3.9 3 109 53,189 TNFRSF11A-ZCCHC2
rs16948098 15 42,006,899 A G 0.06 0.0229 0.0041 1.9 3 108 53,189 FRMD5-WDR76
rs739347 19 54,693,197 T C 0.89 0.0186 0.0034 3.2 3 108 38,231 RPS11-FCGRT
Total Protein
rs3751991 17 16,776,011 A C 0.11 0.0377 0.0059 1.3 3 1010 25,537 TNFRSF13B
rs204999 6 32,217,957 A G 0.74 0.0251 0.0042 3.4 3 109 25,537 6q21.3
Genome-wide significance is defined as p < 5 3 108. The following abbreviations are used: Chr, chromosome; and EAF, effect allele frequency.the European meta-analysis with data from a GWAS of
Japanese ancestry with the aim of (1) identifying addi-
tional loci through increased sample size, (2) assessing
the evidence of heterogeneity in allelic effects between
ethnic groups, and (3) improving the resolution of fine
mapping in associated regions by leveraging the expected
differences in the structure of linkage disequilibrium (LD)
between diverse populations.
The European-ancestry meta-analysis consisted of
53,190 individuals (from 20 GWASs) for serum albumin
and 25,539 individuals (from six GWASs) for total protein
(Tables S1–S3 and Supplemental Data available online).
The procedures followed were approved by the institu-
tional review board committees and are in accordance
with the ethical standards of the institutional committees
on human experimentation. All participants have given
informed consent. Sample and SNP quality control (QC)
were undertaken within each study. Each GWAS was
then imputed at up to 2.5M autosomal SNPs with the
use of CEU (Utah residents with ancestry from northern
and western Europe from the CEPH collection) samples
from phase II of the International HapMap Project.10
Each SNP with minor allele frequency (MAF) >1% that
passed QC was tested for association with serum albumin
and total protein under an additivemodel after adjustment
for study-specific covariates. The results of each GWAS
were corrected for residual population structure using the
genomic control inflation factor11 and were combined
via fixed-effect inverse-variance-weighted meta-analysis.
The results of the meta-analysis were subsequently cor-
rected by a second round of genomic control (lGC ¼ 1.04
for serum albumin and lGC ¼ 1.02 for total protein) to
allow for population differences between studies.
The European-ancestry meta-analysis identified six
genome-wide significant loci (p < 5 3 108) for serum
albumin and two for total protein (Table 1, Figure S1).
These included association signals for serum albumin at746 The American Journal of Human Genetics 91, 744–753, OctoberHPN (MIM 142440)-SCN1B (MIM 600235) (p ¼ 3.3 3
1015), SERPINF2 (MIM 613168)-WDR81 (MIM 614218)
(p ¼ 6.8 3 1013), TNFRSF11A (MIM 603499)-ZCCHC2
(p ¼ 3.9 3 109), and FRMD5-WDR76 (p ¼ 2.0 3 108)
and for total protein on chromosome 6q21.3 (p ¼ 3.4 3
109). We also confirmed the associations previously re-
ported in eastern Asian populations at GCKR-FNDC4 (p ¼
2.9 3 1014) and RPS11-FCGRT (p ¼ 3.2 3 108) for serum
albumin and TNFRSF13B (p ¼ 1.3 3 1010) for total
protein. Inspection of the HPN-SCN1B locus (Figure 1)
provided evidence for two independent association sig-
nals for serum albumin (rs4806073, p ¼ 3.3 3 1015;
rs11671010, p ¼ 1.9 3 1013; CEU r2 ¼ 0.02, 4.3 kb apart).
To perform conditional analyses at this locus, we applied
genome-wide complex trait analysis (GCTA)12 to the
results of the European-ancestry meta-analysis and indi-
vidual-level genotype data from the Atherosclerosis Risk
in Communities Study (8,127 European American individ-
uals, Table S1) and confirmed that both SNPs remained
genome-wide significant after adjustment for the effect
of the other (rs4806073, p ¼ 1.6 3 1012; rs11671010,
p ¼ 1.5 3 1011).
The results of the European meta-analysis were then
combined with a Japanese-ancestry GWAS (BioBank Japan
Project) consisting of 9,380 individuals for serum albumin
and 10,168 individuals for total protein (Tables S1–S3,
Supplemental Data). Sample and SNP QC were undertaken
within the BioBank Japan Project. The GWAS was imputed
at up to 2.5M autosomal SNPs with the use of Han Chinese
in Beijing and Japanese in Tokyo (CHBþJPT) samples from
phase II of the International HapMap Project.10 Each SNP
with MAF >1% that passed QC was then tested for associ-
ation with serum albumin and total protein in the BioBank
Japan Project under an additive model after adjustment for
age and sex, and the results were corrected for residual pop-
ulation structure with the genomic control inflation factor
(lGC ¼ 0.98 for serum albumin and lGC ¼ 1.08 for total5, 2012
Figure 1. Signal Plot of the HPN-SCN1B Locus for Serum Albumin
The two panels present signal plots from the fixed-effect meta-analyses of European-ancestry individuals showing evidence for two inde-
pendent associations in the region only: (A) SNPs tagged by rs4806073 and (B) SNPs tagged by rs11671010. In each panel, the lead SNP is
represented by the purple circle. Each point represents a SNP plotted with their p (on a log10 scale) as a function of genomic position
(build 36). The color coding of all other SNPs indicates LD with the lead SNP (estimated by CEU r2 from phase II HapMap): red, r2 R
0.8; gold, 0.6% r2<0.8; green, 0.4% r2<0.6; cyan, 0.2% r2<0.4; blue, r2<0.2; and gray, r2 unknown. Recombination rates are estimated
from the International HapMap Project, and gene annotations are taken from the University of California Santa Cruz genome browser.protein). The European meta-analysis and the BioBank
Japan Project GWAS were then combined via transethnic
meta-analysis implemented with MANTRA (meta-analysisThe Americof transethnic association studies).13 This approach has
the advantage of allowing for heterogeneity in allelic
effects between ancestry groups by assigning studies toan Journal of Human Genetics 91, 744–753, October 5, 2012 747
clusters according to a Bayesian partition model of simi-
larity in terms of their allele frequency profile. Studies as-
signed to the same cluster have the same allelic effect.
However, each cluster can have different allelic effects.
Fixed-effect meta-analysis is thus equivalent to a Bayesian
partition model with a single cluster of studies.
We observed strong evidence of association, as defined
by a log10 Bayes factor (BF) of 5 (equivalent to prior odds
of association of any SNP with either trait of 1:100,000),14
at all identified loci for both traits (Table 2, Figure S2).
These loci included RPS11-FCGRT for total protein, which
was previously observed in eastern Asian populations but
not at genome-wide significance in our European-ancestry
meta-analysis. The only exception was at the FRMD5-
WDR76 locus (log10BF ¼ 4.79), where the lead SNP from
the Europeanmeta-analysis (rs16948098) was not observed
in the Japanese GWAS and is monomorphic in eastern
Asian (CHB and JPT) HapMap populations.10 Using the
threshold of log10BF> 5 for strong evidence of association,
we identified two additional ‘‘potential’’ loci for serum
albumin and four for total protein (Table 2).
MANTRA revealed little evidence of heterogeneity in
allelic effects between European-ancestry and Japanese
studies at the majority of the serum albumin and total
protein loci (Table 2). The extent of heterogeneity was
assessed through comparison of association BF under a
Bayesian partition model wherein the number of clusters
of studies is unrestricted to that wherein there is a single
cluster, the latter corresponding to homogeneous allelic
effects across all ancestry groups. Subsequent fixed-effect
inverse-variance-weighted meta-analysis across groups of
European and Japanese ancestry (Table S4) revealed one
additional signal for total-protein mapping to ELL2 (MIM
601874, p ¼ 1.1 3 108), although none of the other
potential MANTRA loci showed genome-wide significance
(p < 53 108). Among these potential loci, however, there
was strong evidence of heterogeneity at ARID5B (MIM
608538) for total protein (MANTRA log10BF in favor of
heterogeneity of 6.79). The lead SNP at this locus
(rs2675609) was strongly associated with total protein
only in the Japanese GWAS (p ¼ 1.7 3 106, compared
with p ¼ 0.014 in the European meta-analysis), and the
allelic effects were in opposite directions in the two
ancestry groups (Table 2). Interestingly, the effect-allele
frequency is similar in European-ancestry and Japanese
GWASs, and there is little evidence of variation in LD
structure between CEU and CHBþJPT reference haplotypes
from the 1000 Genomes Project15 (Figure S3). Although
intrastudy phenotypic variation in total protein concen-
trations (such as Ig, which is not available for analyses
here) might contribute to these apparent transethnic dif-
ferences in allelic effects, further investigation is required
to fully elucidate the source of heterogeneity between
ancestry groups.
To assess the improvement in fine-mapping resolution
due to transethnic meta-analysis in serum albumin and
total protein loci, we defined ‘‘credible sets’’ of SNPs748 The American Journal of Human Genetics 91, 744–753, October(J.B. Maller, personal communication) with the strongest
signals of association and, hence, most likely to be causal
(or tagging an unobserved causal variant), on the basis of
European-ancestry GWASs only and then after inclusion
of the Japanese study. At each locus, defined by the
genomic region 500 kb up and downstream of the lead
SNP, we calculated the posterior probability that the jth
SNP is ‘‘causal’’ (or tags an unobserved causal variant) by
fj ¼
BFjP
k
BFk
:
In this expression, BFj denotes the BF in favor of associa-
tion of the jth SNP from the transethnic MANTRA analysis,
and the summation in the denominator is over all SNPs
passingQCacross the locus (J.B.Maller, personal communi-
cation). A 100u% credible set at the locus was then con-
structed through (1) ranking all SNPs according to their
BF and (2) combining ranked SNPs until their cumulative
posterior probability exceeded u. Using this definition,
we observed improved resolution, in terms of the number
of SNPs and the genomic interval covered by the credible
set, at HPN-SCN1B, TNFRSF11A-ZCCHC2, and RPS11-
FCGRT for serum albumin and at TNFRSF13B and the
6q21.3 locus for total protein (Figure 2, Table S5). The
most striking improvements in resolution were observed
at the 6q21.3 locus for total protein, wherein the 99% cred-
ible set was reduced from 14 SNPs (covering 346 kb), to just
three (covering 37 kb). Furthermore, after transethnic
meta-analysis, the posterior probability that the lead SNP
was causal (or tagged an unobserved causal variant) was
more than 95% at GCKR-FNDC4 and SERPINF2-WDR81
for serum albumin and at TNFRSF13B and the 6q21.3 locus
for total protein.
Two of the serum albumin loci, HPN-SCN1B and RPS11-
FCGRT, can be validated by existing mouse models. The
lead SNP at the HPN-SCN1B locus maps to an intron of
HPN, a gene encoding hepsin, a membrane-bound serine
protease that has substrate specificity for basic amino acids
similar to that of proalbumin processing, suggesting a
physiologic role of hepsin in the cleavage of proalbumin
to albumin. We compared serum protein concentrations
between hepsin knockout (KO) mice and wild-type litter
mates16 (Figure 3) using blood samples collected from
the inferior vena cava and analyzed by Consolidated
Veterinary Diagnostics (West Sacramento, CA, USA). In
hepsin/ mice, we observed overwhelming evidence of
reduced serum albumin (p ¼ 9.1 3 1012) and, to a lesser
extent, reduced total protein (p ¼ 1.5 3 105), but not
Ig. At the RPS11-FCGRT locus, KO Fcgrt mice have been
previously demonstrated to manifest low serum albumin
and low serum gamma Ig concentrations.17,18 Further-
more, in humans, two siblings with genetic deficiency of
FcRn due to lack of the b2 microglobumin component
have manifested reduced serum albumin and gamma Ig
concentrations.19 FCGRT encodes the heavy alpha chain
of the FcRn, which prevents lysosomal degradation of5, 2012
Table 2. Loci with Strong Evidence of Association with Serum Albumin and Total Protein after Transethnic MANTRA Analysis of European-Ancestry and Japanese GWASs
Lead SNP Chr
Position
(Build 36)
Alleles European Ancestry GWAS Meta-analysis Japanese GWAS MANTRA Transethnic Meta-analysis
LocusEffect Other EAF Beta SE p Value
Sample
Size EAF Beta SE p Value
Sample
Size
log10 BF
Association
log10 BF
Heterogeneity
Serum Albumin Established Loci
rs1260326 2 27,584,444 T C 0.41 0.0124 0.0016 2.9 3 1014 53,189 0.56 0.0270 0.0050 2.2 3 108 9,380 17.01 0.28 GCKR-FNDC4
rs4806073 19 40,247,030 C T 0.93 0.0257 0.0033 3.3 3 1015 53,187 0.92 0.0380 0.0090 1.3 3 105 9,380 15.81 0.08 HPN-SCN1B
rs11078597 17 1,565,113 C T 0.18 0.0205 0.0029 6.8 3 1013 38,231 0.18 0.0200 0.0060 1.8 3 103 9,380 12.51 0.20 SERPINF2-WDR81
rs694419 18 58,277,092 T C 0.52 0.0093 0.0016 1.2 3 108 53,189 0.05 0.0180 0.0110 9.2 3 102 9,380 7.05 0.11 TNFRSF11A-ZCCHC2
rs2280401 19 54,691,821 A G 0.17 0.0121 0.0024 7.6 3 107 53,189 0.16 0.0240 0.0070 3.1 3 104 9,380 6.96 0.13 RPS11-FCGRT
rs16948098 15 42,006,899 A C 0.06 0.0229 0.0041 1.9 3 108 53,189 0.00 4.79 FRMD5-WDR76
Serum Albumin Additional Potential Loci
rs2293579 11 47,397,334 A G 0.40 0.0093 0.0017 8.0 3 108 53,189 0.26 0.0030 0.0050 5.7 3 101 9,380 5.61 0.05 PSMC3
rs12914385 15 76,685,778 C T 0.61 0.0064 0.0016 8.7 3 105 53,189 0.70 0.0200 0.0050 1.3 3 104 9,380 5.07 0.12 CHRNA3- CHRNA5
Total Protein Established Loci
rs4561508 17 16,789,475 T C 0.11 0.0360 0.0060 1.3 3 109 25,534 0.37 0.0470 0.0700 2.0 3 1011 10,168 16.25 0.00 TNFRSF13B
rs204999 6 32,217,957 A G 0.74 0.0250 0.0040 3.4 3 109 25,537 0.94 0.0420 0.0130 1.7 3 103 10,168 9.01 0.10 6q21.3
rs2280401 19 54,691,821 A G 0.16 0.0120 0.0050 1.5 3 102 25,537 0.16 0.0500 0.0090 6.5 3 108 10,168 5.19 0.96 RPS11-FCGRT
Total Protein Additional Potential Loci
rs3777200 5 95,260,547 T C 0.27 0.0180 0.0040 1.9 3 105 25,524 0.30 0.0290 0.0070 1.1 3 104 10,168 6.57 0.14 ELL2
rs1260326 2 27,584,444 T C 0.44 0.0150 0.0040 1.1 3 104 25,537 0.56 0.0310 0.0070 3.7 3 106 10,168 5.93 0.02 GCKR-FNDC4
rs2675609 10 63,306,537 T C 0.39 0.0090 0.0040 1.4 3 102 25,537 0.43 0.0360 0.0070 1.7 3 106 10,168 5.81 6.79 ARID5B
rs10097731 8 82,190,227 T G 0.15 0.0230 0.0050 1.1 3 105 25,537 0.17 0.0310 0.0090 5.9 3 104 10,168 5.67 0.19 PAG1
Strong evidence is defined as log10 BF > 5. The following abbreviations are used: Chr, chromosome; GWAS, genome-wide association study; MANTRA, meta-analysis of transethnic association studies; EAF, effect allele
frequency; and BF, Bayes factor.
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Figure 2. Fine Mapping of the 6q21.3 Locus for Total Protein
The two panels present signal plots for the MANTRA association signal (A) after transethnic meta-analysis of European-ancestry and
Japanese GWASs and (B) after meta-analysis of the European ancestry GWAS only. Each point represents a SNP passing QC in our
MANTRA analysis, plotted with their BF (on a log10 scale) as a function of genomic position (build 36). In each panel, the lead SNP is
represented by the purple circle. The color coding of all other SNPs indicates LD with the lead SNP (estimated by CEU r2 from phase
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Figure 3. Serum Albumin, Total Protein, and Serum Globulin
Concentrations and Albumin-to-Ig Ratio in Wild-Type and
hepsin/ Mice
Data are presented as mean5 SD, and the number of mice in each
experimental group is shown in parentheses. Results for serum
albumin are shown in (A); for total protein in (B); for serum glob-
ulin in (C); and the albumin-to-Ig ratio (A/Ig ratio) in wild-type
(WT) and hepsin/ (KO) mice in (D). Statistical differences are
shown by p values. Note the significantly lower serum albumin
concentrations, but not Ig concentrations, in KO mice compared
to WT mice.albumin and Ig in lysosomes and thereby extends their
serum half-life.17
To gain insights into the possible functional role of
other serum albumin and total protein loci, we began by
performing expression quantitative trait locus (eQTL)
mapping using data derived from 1,469 whole blood
samples.20 Gene expression levels were measured from
peripheral blood and assayed in 1,240 individuals with
Illumina HT12 v3 and in 229 individuals with Illumina
H8 v2 BeadChip arrays. Both sets were independently
quantile-normalized after log2 transformation and subse-
quently corrected for 50 principal components obtained
from the gene expression probe covariance matrix. To inte-
grate both data sets, genotype data were imputed up to
2.5M autosomal SNPs with the use of CEU samples from
phase II of the International HapMap Project.10 SNPs of
low frequency (MAF < 5%) or with deviation from
Hardy-Weinberg equilibrium (p < 104) were excluded
from the subsequent analysis. Cis-eQTL effects (within 1
Mb of the probe) were determined with Spearman’s ranked
correlation, and meta-analysis between the two data sets
was performed with the use of weighted Z scores. The false
discovery rate (FDR) was then assessed by permutation.
Using this approach, we mapped lead SNPs at four of the
identified loci (GCKR-FNDC4, SERPINF2-WDR81, and
RPS11-FCGRT for serum albumin; 6q21.3 for total protein)
to cis expression levels of 18 genes (Table S6). The strongest
associations were observed for expression of NOSIP (p ¼
2.4 3 1017 at RPS11-FCGRT) and HLA-DQA1 (MIM
146880) /HLA-DQA2 (MIM 613503, p ¼ 9.1 3 1036 at
6q21.3). NOSIP (nitric oxide synthase interacting protein)
inhibits endothelial nitric oxide synthesis, whereas HLA-
DQA1/2 is a human leukocyte antigen (HLA) class II
antigen with an immune system role related to processing
and presentation of antigen peptides.
We noticed that the lead SNP at the GCKR-FNDC4
locus (rs1260326, c.1337T>C [p. Leu446Pro]; RefSeq NM_
001486.3) is a GCKR missense mutation with moderate
predicted functional impact by snpEff, and has been previ-
ously associated with several metabolic traits, as well as
kidney, liver, and hematologic phenotypes (Table S7). We
used data from the 1000 Genomes Project15 to search for
additional coding variants with predicted function in
strong LD (r2 > 0.5 in 283 individuals of European
ancestry) with lead SNPs at our identified serum albumin
and total protein loci (Table S8). Across serum albumin
loci, two nonsynonymous SNPs mapped to SERPINF2, a
gene encoding an inhibitor of plasmin which degrades
plasma fibrin and other proteins, and one nonsynony-
mous SNP mapped to CHRNA5 (MIM 118505), a nicotinic
acetylcholine receptor gene associated with smoking
behavior21,22 and lung cancer.23 For total protein, nonsy-II HapMap): red, r2 R 0.8; gold, 0.6 % r2<0.8; green, 0.4% r2<0.6; c
nation rates are estimated from the International HapMap Project a
Santa Cruz genome browser. In each panel, the gray-shaded region
set of SNPs.
The Americnonymous SNPs mapped to TNFRSF13B and ELL2, and to
PPT2 (MIM 603298) and EGFL8 (MIM 609897) at the
6q21.3 locus. Mutations in TNFRSF13B cause immunodefi-
ciency common variable type 2 (MIM 240500), character-
ized by hypogammaglobulinemia and recurrent bacterial
infections due to failure of b cell differentiation and
impaired production of Ig. They also cause selective IgA
deficiency 2 (MIM 609529), the most common primary
immunodeficiency, affecting 1 in 600 individuals in the
western world. ELL2 product directs Ig secretion in plasma
cells, and the 6q21.3 major histocompatibility complex
class III region encompasses a number of genes involved
in autoimmunity, inflammation, and complement pro-
teins. Interrogation of the National Human Genome
Research Institute (NHGRI) GWAS catalog24 highlighted
that lead SNPs at ten of the identified loci have themselves
been reported or are in LD (r2 > 0.5 in 283 individuals of
European ancestry) with those disclosed, for a diverse
range of human complex traits (Table S7) but are enriched
for metabolic phenotypes that are associated with, or are
direct products of, protein metabolism.
Finally, we used the human interactome database (Cyto-
scape) to construct an interaction network consisting ofyan, 0.2% r2<0.4; blue, r2<0.2; and gray, r2 unknown. Recombi-
nd gene annotations are taken from the University of California
s correspond to the genomic interval covered by a 99% credible
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250 proteins that directly interact with genes in the identi-
fied serum albumin and total protein loci reported in Table
2. For identifying molecular complexes within this first-
degree interaction network, cluster analyses were
performed with the FAG-EC algorithm, implemented in
the ClusterViz plug-in, with standard settings applied. In
total, 16 distinct clusters were identified, including three
large complexes (Figure S4) that were carried forward for
further analysis. Functional enrichment analyses within
these clusters were performed following defined pathways
from BioCarta, KEGG, PANTHER, and Reactome via the
Database for Annotation, Visualization, and Integrated
Discovery (DAVID). The most significantly enriched clus-
ters from protein interaction network analyses incorpo-
rated ribosomal functioning and protein translation,
proteasomal protein degradation, and immune-response
signaling (Table S9). As a complementary approach, we
applied an implementation of gene-set enrichment anal-
ysis (MAGENTA25) to identify whether defined biological
pathways from BioCarta, Gene Ontology, Ingenuity,
KEGG, PANTHER, and Reactome were enriched in the
leading-edge fraction of the meta-analysis. In brief, gene
association p values were calculated on the basis of meta-
analysis summary statistics for SNPs within a 110-kb-
upstream and 40-kb-downstream window. These gene
scores were then corrected for gene size, number of SNPs,
and the LD between them, and subsequently ranked by
p value. Enrichment in the 75th and 95th percentiles was
assessed for significance by comparison with 10,000
randomly generated pathways. Using an FDR threshold
of 5%, we observed significant overrepresentation of genes
assigned to three pathways: RNA- (FDR ¼ 0.044), sensory-
perception- (FDR ¼ 0.027), and protein-trafficking-related
pathways (FDR ¼ 0.043-0.044) (Table S10).
In conclusion, we have identified six loci for serum
albumin concentration and three for total protein at
genome-wide significance. These loci harbor genes that
fall across a diverse range of biological pathways, including
those involved in biomarkers, immune regulation, and dis-
ease, but are enriched for those relevant to the synthesis
and degradation of serum protein. By combining GWAS
data fromEuropean and Japanese populations,we observed
some evidence of heterogeneity in allelic effects between
ancestry groups and have demonstrated substantial im-
provements in the localization of potential causal variants.
Taken together, our results highlight the advantages of
transethnic meta-analysis for the discovery and fine
mapping of complex trait loci and provide initial insights
into the underlying genetic architecture of serum protein
concentrations and their association with human disease.Supplemental Data
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